Citations

Showing 10 of 108083 citations.

MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia
Abeykoon, Jithma P. , Paludo, Jonas , King, Rebecca L. , Ansell, Stephen M. , LaPlant, Betsy, Halvorson, Alese E. , Gonsalves, Wilson I. , Dingli, David , Lacy, Martha Q. , He, Rong , Kourelis, Taxiarchis , Reeder, Craig B. , Novak, Anne J. , McPhail, Ellen D. , Viswanatha, David S., Witzig, Thomas E. , Go, Ronald S. , Leung, Nelson , Lin, Yi , Thompson, Carrie A. , Hayman, Suzanne R. , Kyle, Robert A. , Kumar, Shaji , Kapoor, Prashant , LaPlant, Betsy R, Gonsalves, Wilson , Witzig, T.E. , Go, Ronald S , Buadi, Francis K. , Leung, Nelson , McPhail, Ellen Darcy , Paludo, Jonas , Dingli, David , Lin, Yi , Gertz, Morie A. , Fang, Hong , Rajkumar, S. Vincent , Habermann, Thomas M. , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | October 28, 2017 | Volume: 93 | Issue: 2 | Pages: 187-194

10.1002/ajh.24955 | PMID 29080258 Get It

AbstractWaldenström macroglobulinemia (WM) is an immunoglobulin M‐associated lymphoma, with majority of cases demonstrating MYD88 locus alteration, most commonly, MYD88L265P. Owing to low prevalence of the wild‐type (WT) MYD88 genotype in WM, clinically relevant data in this patient population are sparse, with one study showing nearly a 10‐fold increased risk of mortality in this subgroup compared to patients with MYD88L265P mutation. We studied a large cohort of patients with MYD88L265P and MYD88WT WM, evaluated at Mayo Clinic, Rochester, between 1995 and 2016, to specifically assess the impact of these genotypes on clinical course. Of 557 patients, MYD88L265P mutation status, as determined by allele‐specific polymerase chain reaction, was known in 219, and 174 (79%) of those exhibited MYD88L265P, 157 of 174 patients had active disease. Of 45 (21%) patients with MYD88WT genotype, 44 had active disease. The estimated median follow‐up was 7.0 years; median overall survival was 10.2 years (95% CI: 8.4‐16.5) for MYD88L265P versus 13.9 years (95% CI: 6.4‐29.3) for the MYD88WT (P = 0.86). The time‐to‐next therapy from frontline treatment and the presenting features were similar in the two patient populations. For patients with smoldering WM at diagnosis, the median time‐to‐progression to active disease was 2.8 years (95% CI: 2.2‐3.8) in the MYD88L265P cohort and 1.9 years (95% CI: 0.7‐3.1) in the MYD88WT cohort (P = 0.21). The frequency of transformation to high‐grade lymphoma, or the development of therapy‐elated myelodysplastic syndrome was higher in the MYD88WT cohort (16% versus 4% in the MYD88L265P, P = 0.009). In conclusion, MYD88L265P mutation does not appear to be a determinant of outcome, and its presence may not be a disease‐defining feature in WM. Our findings warrant external validation, preferably through prospective studies.
Bone Grafting for Scaphoid Nonunions: Is Free Vascularized Bone Grafting Superior for Scaphoid Nonunion?
Aibinder, William R. , Wagner, Eric R. , Wagner, Eric R , Bishop, Allen T. , Shin, Alexander Y. , Aibinder, William R

Mayo Clinic

HAND | October 28, 2017 | Volume: 14 | Issue: 2 | Pages: 217-222

10.1177/1558944717736397 | PMID 29078719 Get It

Background: Nonvascularized bone grafting (NVBG) and vascularized bone grafts (VBGs) have been used to treat scaphoid nonunions. A comparison of a single institution’ s experience using structural iliac crest bone graft (ICBG), 1,2-intercompartmental supraretinacular artery (1,2-ICSRA), and medial femoral condyle (MFC) grafts to treat scaphoid nonunions was undertaken. Methods: Thirty-one patients underwent ICBG, 33 patients underwent 1,2-ICSRA, and 45 patients underwent MFC grafting. Mean time to follow-up was 16 months (range, 2-153). Twenty-three percent used tobacco products. Mean age was 24 years (range, 11-66), with 86% male patients. Outcomes included union rate, time to healing, range of motion, complications, and reoperations. Results: Union rates and mean time to union were 71% and 19 weeks for the ICBG group, 79% and 26 weeks for the 1,2-ICSRA group, and 89% and 16 weeks for the MFC group, respectively. Failure of union was associated with tobacco use but not with age, gender, time from injury to surgery, or type of fixation. There was no significant difference between the groups regarding range of motion or strength. Conclusions: These findings demonstrate the need for careful patient selection. In patients with the most complicated scaphoid nonunions (avascular necrosis, carpal collapse, and previous surgeries), the MFC group had the highest union rate and fastest time to union. Patients with risk factors for failure should be counseled on the outcomes and possible need for salvage fusion surgery.
Associations of Nocturnal Blood Pressure With Cognition by Self‐Identified Race in Middle‐Aged and Older Adults: The GENOA (Genetic Epidemiology Network of Arteriopathy) Study
Yano, Yuichiro , Butler, Kenneth R. , Hall, Michael E. , Schwartz, Gary L. , Lirette, Seth T. , Wilson, James G. , Hall, John E. , Turner, Stephen T. , Butler, Kenneth R , Knopman, David S. , Jones, Daniel W. , Correa, Adolfo , Mosley, Thomas H. , Lirette, Seth

Mayo Clinic

Journal of the American Heart Association | October 28, 2017 | Volume: 6 | Issue: 11 | Pages: No page available

10.1161/jaha.117.007022 | PMID 29079569 Get It

Background Whether the association of blood pressure ( BP ) during sleep (nocturnal BP ) with cognition differs by race is unknown. Methods and Results Participants in the GENOA (Genetic Epidemiology Network of Arteriopathy) Study underwent ambulatory BP measurements, brain magnetic resonance imaging, and cognitive function testing (the Rey Auditory Verbal Learning Test, the Digit Symbol Substitution Task, and the Trail Making Test Part B) between 2000 and 2007. We examined multivariable linear regression models of the nocturnal BP ‐cognition association. Among 755 participants (mean age, 63 years; 64% women; 42% self‐identified black race; 76% taking antihypertensive medication), mean nocturnal systolic BP ( SBP )/diastolic BP was 126/69 mm Hg, daytime SBP / diastolic BP level was 139/82 mm Hg, and mean reduction in SBP from day to night (dipping) was 9%. Among the entire sample, a race interaction was observed in Digit Symbol Substitution Task and Trail Making Test Part B (both P <0.15). Race‐stratified analyses showed that a 1‐ SD increase in nocturnal SBP levels was associated with poorer Digit Symbol Substitution Task and log‐transformed Trail Making Test Part B scores (unstandardized regression coefficient [95% confidence interval ]: −1.98 [−3.28 to −0.69] and 0.06 [0.004–0.12]; both P< 0.05) in black but not white individuals. Additional adjustments for white matter hyperintensity volumes or brain atrophy, measured via brain magnetic resonance imaging, did not change the results. Results were similar when nocturnal SBP dipping was assessed as the exposure, yet daytime SBP levels yielded no association with cognition. Conclusions Nocturnal SBP measurements may be useful in assessing the potential risk for lower cognitive function in middle‐aged and older adults, particularly in black individuals.
The Ethnopharmacologic Contribution to Bioprospecting Natural Products
Buenz, Eric J. , Bauer, Brent A. , Verpoorte, Robert

Mayo Clinic

Annual Review of Pharmacology and Toxicology | October 27, 2017 | Volume: 58 | Issue: 1 | Pages: 509-530

10.1146/annurev-pharmtox-010617-052703 | PMID 29077533 Get It

Descriptions of the use of natural products in traditional medicine have served as starting points for new therapeutics. The details of the traditional use of these organisms can provide important information for future drug discovery and development efforts. Recent technologic advances provide the framework to leverage ethnopharmacologic data in the drug discovery process. Information on the traditional harvest, preparation, storage, and administration of the organisms, and the natural products they contain, provides valuable details regarding characteristics of the active compounds. Importantly, researchers can now rapidly analyze and identify the multiple, and often synergistic, compounds contained in these natural products. Although we are entering the acme of ethnopharmacology, where information regarding the traditional use of organisms can provide valuable natural product leads and accelerate the identification of new therapeutics, this ethnopharmacologic resource is threatened by the loss of traditional medicine knowledge and extinction of organisms.
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups
Tjärnlund, Anna, Bottai, Matteo , Pilkington, Clarissa , Visser, Marianne de, Amato, Anthony A. , Barohn, Richard J., Liang, Matthew H. , Arnardottir, Snjólaug, Chinoy, Hector , Dankó, Katalin , Dimachkie, Mazen M. , Torre, Ignacio García‐De La , Gordon, Patrick , Hayashi, Taichi, Katz, James D. , Kohsaka, Hitoshi, Lachenbruch, Peter A., Lang, Bianca , Olesińska, Marzena , Reed, Ann M. , Rutkowska‐Sak, Lidia , Sanner, Helga , Selva-O’Callaghan, Albert , Song, Yeong‐Wook, Vencovský, Jiří , Ytterberg, Steven R. , Miller, Frederick W. , Rider, Lisa G. , Vencovsky, Jiri , Chinoy, Hector , Selva O'Callaghan, Albert , Lundberg, Ingrid E. , Werth, Victoria P. , Visser, Marianne de, Alfredsson, Lars , Singh, Jasvinder A. , Aggarwal, Rohit , Cooper, Robert G. , Feldman, Brian Michael , Li, Yuhui , Oddis, Chester V. , Song, Yeong-Wook, García-De La Torre, Ignacio , Dimachkie, Mazen M

Mayo Clinic

Arthritis & Rheumatology | October 27, 2017 | Volume: 69 | Issue: 12 | Pages: 2271-2282

10.1002/art.40320 | PMID 29106061 Get It

Objective To develop and validate new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups. Methods Candidate variables were assembled from published criteria and expert opinion using consensus methodology. Data were collected from 47 rheumatology, dermatology, neurology, and pediatric clinics worldwide. Several statistical methods were utilized to derive the classification criteria. Results Based on data from 976 IIM patients (74% adults; 26% children) and 624 non‐IIM patients with mimicking conditions (82% adults; 18% children), new criteria were derived. Each item is assigned a weighted score. The total score corresponds to a probability of having IIM. Subclassification is performed using a classification tree. A probability cutoff of 55%, corresponding to a score of 5.5 (6.7 with muscle biopsy) “probable IIM,” had best sensitivity/specificity (87%/82% without biopsies, 93%/88% with biopsies) and is recommended as a minimum to classify a patient as having IIM. A probability of ≥90%, corresponding to a score of ≥7.5 (≥8.7 with muscle biopsy), corresponds to “definite IIM.” A probability of <50%, corresponding to a score of <5.3 (<6.5 with muscle biopsy), rules out IIM, leaving a probability of ≥50–<55% as “possible IIM.” Conclusion The European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for IIM have been endorsed by international rheumatology, dermatology, neurology, and pediatric groups. They employ easily accessible and operationally defined elements, and have been partially validated. They allow classification of “definite,” “probable,” and “possible” IIM, in addition to the major subgroups of IIM, including juvenile IIM. They generally perform better than existing criteria.
Imaging Characteristics Predict Operative Difficulty Mobilizing the Sciatic Nerve for Proximal Hamstring Repair
Wilson, Thomas J. , Howe, B. Matthew, Spinner, Robert J. , Krych, Aaron J. , Krych, Aaron J

Mayo Clinic

Neurosurgery | October 27, 2017 | Volume: 83 | Issue: 5 | Pages: 931-939

10.1093/neuros/nyx553 | PMID 29145673 Get It

Abstract BACKGROUND Repair of proximal hamstring avulsions requires mobilization of the sciatic nerve away from the tendon stump, which can be achieved with varying difficulty depending on the degree of scar formation and adherence. Predicting when a scarred, adherent, difficult-to-mobilize nerve will be encountered has been difficult. OBJECTIVE To identify clinical and/or radiological factors predictive of a difficult intraoperative dissection of the sciatic nerve during proximal hamstring repair. METHODS We retrospectively reviewed the medical records and preoperative magnetic resonance imaging of consecutive patients undergoing proximal hamstring repair. We compared the groups with and without a difficult sciatic nerve dissection. RESULTS The total cohort consisted of 67 patients. Factors found to increase the likelihood of a difficult sciatic nerve dissection included complete conjoint tendon avulsion, higher maximal amount of tendon retraction, higher degree of imaging abnormality in the sciatic nerve, and higher degree of circumferential relationship of hematoma to the sciatic nerve. At a threshold of 23 for the Sciatic Nerve Dissection Score, the positive and negative predictive values were 53% and 88%, respectively. For the decision tree, the positive and negative predictive values were 75% and 87%, respectively. CONCLUSION We have identified imaging factors associated with a scarred, adherent sciatic nerve that predict a difficult dissection during proximal hamstring repair. We have developed 2 novel methods—the Sciatic Nerve Dissection Score and a decision tree—that can be applied to predict the probability of a difficult sciatic nerve dissection at the time of surgical repair.
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas
Carlson, Matthew L. , Adewumi, Dare A, Hadjipanayis, Constantinos G., Uhm, Joon H. , Gompel, Jamie J. Van , Agazzi, Siviero , Adewumi, Dare A., Olson, Jeffrey J.

Mayo Clinic

Neurosurgery | October 27, 2017 | Volume: 82 | Issue: 2 | Pages: E52-E54

10.1093/neuros/nyx516 | PMID 29309638 Get It

Abstract MEDICAL THERAPY Target Population Adults with histologically proven or suspected vestibular schwannomas with neurofibromatosis type 2 (NF2). Question What is the role of bevacizumab in the treatment of patients with vestibular schwannomas? Recommendations Level 3: It is recommended that bevacizumab be administered in order to radiographically reduce the size or prolong tumor stability in patients with NF2 without surgical options. Level 3: It is recommended that bevacizumab be administered to improve hearing or prolong time to hearing loss in patients with NF2 without surgical options. Question Is there a role for lapatinib, erlotinib, or everolimus in the treatment of patients with vestibular schwannomas? Recommendations Level 3: Lapatinib may be considered for use in reducing vestibular schwannoma size and improvement in hearing in NF2. Level 3: Erlotinib is not recommended for use in reducing vestibular schwannoma size or improvement in hearing in patients with NF2. Level 3: Everolimus is not recommended for use in reducing vestibular schwannoma size or improvement in hearing in NF2. Question What is the role of aspirin, to augment inflammatory response, in the treatment of patients with vestibular schwannomas? Target Population Any patient with a vestibular schwannoma undergoing observation. Recommendation Level 3: It is recommended that aspirin administration may be considered for use in patients undergoing observation of their vestibular schwannomas. Question Is there a role for treatment of vasospasm, ie, nimodipine or hydroxyethyl starch, perioperatively to improve facial nerve outcomes in patients with vestibular schwannomas? Target Population Adults with histologically proven or suspected vestibular schwannomas. Recommendation Level 3: Perioperative treatment with nimodipine (or with the addition of hydroxyethyl starch) should be considered to improve postoperative facial nerve outcomes and may improve hearing outcomes. PREHABILITATION Question Is there a role for preoperative vestibular rehab or vestibular ablation with gentamicin for patients surgically treated for vestibular schwannomas? Target Population Adults with histologically proven or suspected vestibular schwannomas. Recommendations Level 3: Preoperative vestibular rehabilitation is recommended to aid in postoperative mobility after vestibular schwannoma surgery. Level 3: Preoperative gentamicin ablation of the vestibular apparatus should be considered to improve postoperative mobility after vestibular schwannoma surgery. SURGICAL THERAPY Question Does endoscopic assistance make a difference in resection or outcomes in patients with vestibular schwannomas? Target Population Vestibular schwannoma patients, who are surgical candidates. Inclusion in this analysis required resection utilizing the endoscope, either as the primary operative visualization or microscopic assistance with more than 20 patients treated. Recommendation Level 3: Endoscopic assistance is a surgical technique that the surgeon may choose to use in order to aid in visualization. The full guideline can be found at: https://www.cns.org/guidelines/guidelines-management-patients-vestibular-schwannoma/chapter_9.
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Pathological Methods and Prognostic Factors in Vestibular Schwannomas
Sughrue, Michael E. , Fung, Kar‐Ming , Peterson, Jo Elle G., Gompel, Jamie J. Van , Olson, Jeffrey J.

Mayo Clinic

Neurosurgery | October 27, 2017 | Volume: 82 | Issue: 2 | Pages: E47-E48

10.1093/neuros/nyx514 | PMID 29309662 Get It

Abstract TARGET POPULATION Adults diagnosed with vestibular schwannomas. QUESTION 1 What is the prognostic significance of Antoni A vs B histologic patterns in vestibular schwannomas? RECOMMENDATION No recommendations can be made due to a lack of adequate data. QUESTION 2 What is the prognostic significance of mitotic figures seen in vestibular schwannoma specimens? RECOMMENDATION No recommendations can be made due to a lack of adequate data. QUESTION 3 Are there other light microscopic features that predict clinical behavior of vestibular schwannomas? RECOMMENDATION No recommendations can be made due to a lack of adequate data. QUESTION 4 Does the KI-67 labeling index predict clinical behavior of vestibular schwannomas? RECOMMENDATION No recommendations can be made due to a lack of adequate data. QUESTION 5 Does the proliferating cell nuclear antigen labeling index predict clinical behavior of vestibular schwannomas? RECOMMENDATION No recommendations can be made due to a lack of adequate data. QUESTION 6 Does degree of vascular endothelial growth factor expression predict clinical behavior of vestibular schwannomas? RECOMMENDATION No recommendations can be made due to a lack of adequate data. The full guideline can be found at: https://www.cns.org/guidelines/guidelines-management-patients-vestibular-schwannoma/chapter_6.
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Intraoperative Cranial Nerve Monitoring in Vestibular Schwannoma Surgery
Vivas, Esther , Carlson, Matthew L. , Neff, Brian A., Shepard, Neil T., McCracken, D. Jay , Sweeney, Alex D. , Olson, Jeffrey J.

Mayo Clinic

Neurosurgery | October 27, 2017 | Volume: 82 | Issue: 2 | Pages: E44-E46

10.1093/neuros/nyx513 | PMID 29309641 Get It

Abstract FACIAL NERVE MONITORING Question 1 Does intraoperative facial nerve monitoring during vestibular schwannoma surgery lead to better long-term facial nerve function? Target Population This recommendation applies to adult patients undergoing vestibular schwannoma surgery regardless of tumor characteristics. Recommendation Level 3: It is recommended that intraoperative facial nerve monitoring be routinely utilized during vestibular schwannoma surgery to improve long-term facial nerve function. Question 2 Can intraoperative facial nerve monitoring be used to accurately predict favorable long-term facial nerve function after vestibular schwannoma surgery? Target Population This recommendation applies to adult patients undergoing vestibular schwannoma surgery. Recommendation Level 3: Intraoperative facial nerve can be used to accurately predict favorable long-term facial nerve function after vestibular schwannoma surgery. Specifically, the presence of favorable testing reliably portends a good long-term facial nerve outcome. However, the absence of favorable testing in the setting of an anatomically intact facial nerve does not reliably predict poor long-term function and therefore cannot be used to direct decision-making regarding the need for early reinnervation procedures. Question 3 Does an anatomically intact facial nerve with poor electromyogram (EMG) electrical responses during intraoperative testing reliably predict poor long-term facial nerve function? Target Population This recommendation applies to adult patients undergoing vestibular schwannoma surgery. Recommendation Level 3: Poor intraoperative EMG electrical response of the facial nerve should not be used as a reliable predictor of poor long-term facial nerve function. COCHLEAR NERVE MONITORING Question 4 Should intraoperative eighth cranial nerve monitoring be used during vestibular schwannoma surgery? Target Population This recommendation applies to adult patients undergoing vestibular schwannoma surgery with measurable preoperative hearing levels and tumors smaller than 1.5 cm. Recommendation Level 3: Intraoperative eighth cranial nerve monitoring should be used during vestibular schwannoma surgery when hearing preservation is attempted. Question 5 Is direct monitoring of the eighth cranial nerve superior to the use of far-field auditory brain stem responses? Target Population This recommendation applies to adult patients undergoing vestibular schwannoma surgery with measurable preoperative hearing levels and tumors smaller than 1.5 cm. Recommendation Level 3: There is insufficient evidence to make a definitive recommendation. The full guideline can be found at: https://www.cns.org/guidelines/guidelines-manage-ment-patients-vestibular-schwannoma/chapter_4.